---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-095097"
form_type: "8-K"
ticker: "ATOS"
cik: "0001488039"
company_name: "ATOSSA THERAPEUTICS, INC."
filed_at: "2024-08-12T23:59:59+00:00"
generated_at: "2026-05-31T10:01:14.359973+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Atossa reports $79.5M cash, no debt; EVANGELINE Phase 2 40mg cohort shows 100% disease control rate

## Summary
- Ended Q2 2024 with $79.5M cash and cash equivalents, no debt; interest income $1.1M in Q2.
- Total operating expenses $7.1M in Q2 2024 vs $7.8M in Q2 2023, down 9% YoY.
- Phase 2 EVANGELINE 40mg cohort achieved 100% disease control rate at 24 weeks for ER+/HER2- breast cancer.
- Completed enrollment in EVANGELINE 80mg PK run-in cohort and dosing in Phase 2 Karisma-Endoxifen trial (240 patients).
- Appointed Heather Rees as CFO; joined Russell 3000 Index effective June 28, 2024.

## SEC filing metadata
- accession: 0000950170-24-095097
- form_type: 8-K
- ticker: ATOS
- cik: 0001488039
- company_name: ATOSSA THERAPEUTICS, INC.
- filed_at: 2024-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1488039/000095017024095097/0000950170-24-095097-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1488039/000095017024095097/atos-20240812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-095097
- JSON: https://secwatch.observer/filing/0000950170-24-095097.json
- Plain text: https://secwatch.observer/filing/0000950170-24-095097.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.